Does biologic survival depend on co-prescribed methotrexate dose in established rheumatoid arthritis? A real-world study.

Objective: Several seminal studies have suggested that a combination therapy of biologics with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) improve disease outcomes in rheumatoid arthritis (RA). Hence, most guidelines reflect this practice. It has also been shown that methotrexate (MTX) at a dose of 8-10 mg/week is perhaps sufficient to achieve better outcomes in early RA.

Eye and foot checks in patients with diabetes on haemodialysis: Are they done, and who does them?

Aim: To determine if retinal and foot checks are carried out on patients with diabetes receiving haemodialysis.

Methods: Eighty-four patients with diabetes receiving haemodialysis were asked if they recalled having eye and foot screening in the last year, and if so, by whom was the check done.

Results: Seventy-seven (91.